Brief: A1m Pharma: Positive Top-Line Results From Phase 1A Study Of ROSgard

Disruptive Pharma AB (publ)

19/09/2019 12:44

Sept 19 (Reuters) - A1M Pharma AB  A1M.ST :
    * A1M PHARMA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM A PHASE 1A STUDY OF ROSGARD
    * RESULTS SHOW THAT SINGLE DOSES OF ROSGARD ARE WELL TOLERATED WITH FAVOURABLE
PHARMACOKINETIC
CHARACTERISTICS
    * A1M PHARMA TODAY ANNOUNCED THAT RESULTS FROM INITIAL PART OF A PHASE 1A STUDY SHOW THAT
INVESTIGATIONAL DRUG ROSGARD HAS A GOOD SAFETY PROFILE AND THAT PLASMA CONCENTRATIONS THAT ARE
EXPECTED TO HAVE A THERAPEUTIC EFFECT WERE ACHIEVED
    * PLASMA CONCENTRATIONS THAT ARE EXPECTED TO HAVE A THERAPEUTIC EFFECT WERE ACHIEVED AND NO
SERIOUS SIDE EFFECTS WERE REPORTED
    * RESULTS FORM BASIS FOR NEXT STAGE OF DEVELOPMENT, WHERE CO PLANS TO STUDY MULTIPLE
ASCENDING
DOSES OF ROSGARD IN HEALTHY SUBJECTS
    * NEXT STAGE STUDY, WHICH REQUIRES SEPARATE REGULATORY APPROVAL, IS EXPECTED TO TAKE ABOUT 3
MTHS
TO COMPLETE

Source text for Eikon:  ID:nBQNjJ8xV 
Further company coverage:  A1M.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))